Temasek Holdings Private Ltd Sells 13,932 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Temasek Holdings Private Ltd reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,057,248 shares of the medical research company's stock after selling 13,932 shares during the period. Thermo Fisher Scientific accounts for 2.2% of Temasek Holdings Private Ltd's holdings, making the stock its 14th biggest holding. Temasek Holdings Private Ltd owned 0.28% of Thermo Fisher Scientific worth $550,012,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Barrett & Company Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. FPC Investment Advisory Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Pillar Financial Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Missouri Trust & Investment Co bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $30,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TMO. Barclays cut their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Royal Bank of Canada cut their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Scotiabank cut their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $607.43.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. This represents a 7.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock valued at $7,305,942 over the last three months. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $0.45 during trading hours on Tuesday, reaching $413.47. The stock had a trading volume of 2,141,884 shares, compared to its average volume of 1,845,527. The stock's fifty day simple moving average is $449.99 and its 200 day simple moving average is $508.22. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $156.08 billion, a PE ratio of 25.01, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the business earned $5.11 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.